nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Mediastinal disorder—Cisplatin—bone cancer	0.00241	0.00241	CcSEcCtD
Tobramycin—Dry eye—Doxorubicin—bone cancer	0.00233	0.00233	CcSEcCtD
Tobramycin—Erythema—Cisplatin—bone cancer	0.00232	0.00232	CcSEcCtD
Tobramycin—Rash maculo-papular—Doxorubicin—bone cancer	0.0023	0.0023	CcSEcCtD
Tobramycin—Renal failure acute—Methotrexate—bone cancer	0.00229	0.00229	CcSEcCtD
Tobramycin—Thrombophlebitis—Epirubicin—bone cancer	0.00229	0.00229	CcSEcCtD
Tobramycin—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.00228	0.00228	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Methotrexate—bone cancer	0.00224	0.00224	CcSEcCtD
Tobramycin—Eye pain—Epirubicin—bone cancer	0.0022	0.0022	CcSEcCtD
Tobramycin—Vision blurred—Cisplatin—bone cancer	0.00219	0.00219	CcSEcCtD
Tobramycin—Lethargy—Methotrexate—bone cancer	0.00216	0.00216	CcSEcCtD
Tobramycin—Ill-defined disorder—Cisplatin—bone cancer	0.00216	0.00216	CcSEcCtD
Tobramycin—Anaemia—Cisplatin—bone cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Renal failure acute—Epirubicin—bone cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Thrombophlebitis—Doxorubicin—bone cancer	0.00212	0.00212	CcSEcCtD
Tobramycin—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.00211	0.00211	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Epirubicin—bone cancer	0.0021	0.0021	CcSEcCtD
Tobramycin—Malaise—Cisplatin—bone cancer	0.0021	0.0021	CcSEcCtD
Tobramycin—Renal impairment—Epirubicin—bone cancer	0.00208	0.00208	CcSEcCtD
Tobramycin—Leukopenia—Cisplatin—bone cancer	0.00208	0.00208	CcSEcCtD
Tobramycin—Eye pain—Doxorubicin—bone cancer	0.00203	0.00203	CcSEcCtD
Tobramycin—Lethargy—Epirubicin—bone cancer	0.00202	0.00202	CcSEcCtD
Tobramycin—Renal failure acute—Doxorubicin—bone cancer	0.00199	0.00199	CcSEcCtD
Tobramycin—Myalgia—Cisplatin—bone cancer	0.00198	0.00198	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00197	0.00197	CcSEcCtD
Tobramycin—Discomfort—Cisplatin—bone cancer	0.00196	0.00196	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Doxorubicin—bone cancer	0.00194	0.00194	CcSEcCtD
Tobramycin—Renal impairment—Doxorubicin—bone cancer	0.00193	0.00193	CcSEcCtD
Tobramycin—Anaphylactic shock—Cisplatin—bone cancer	0.0019	0.0019	CcSEcCtD
Tobramycin—Lethargy—Doxorubicin—bone cancer	0.00187	0.00187	CcSEcCtD
Tobramycin—Nervous system disorder—Cisplatin—bone cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Thrombocytopenia—Cisplatin—bone cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Blood creatinine increased—Epirubicin—bone cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Dehydration—Epirubicin—bone cancer	0.00184	0.00184	CcSEcCtD
Tobramycin—Skin disorder—Cisplatin—bone cancer	0.00184	0.00184	CcSEcCtD
Tobramycin—Asthma—Methotrexate—bone cancer	0.00183	0.00183	CcSEcCtD
Tobramycin—Dry skin—Epirubicin—bone cancer	0.00182	0.00182	CcSEcCtD
Tobramycin—Eosinophilia—Methotrexate—bone cancer	0.00181	0.00181	CcSEcCtD
Tobramycin—Anorexia—Cisplatin—bone cancer	0.00181	0.00181	CcSEcCtD
Tobramycin—Hypokalaemia—Epirubicin—bone cancer	0.0018	0.0018	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.00178	0.00178	CcSEcCtD
Tobramycin—Muscular weakness—Epirubicin—bone cancer	0.00175	0.00175	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00173	0.00173	CcSEcCtD
Tobramycin—Blood creatinine increased—Doxorubicin—bone cancer	0.00172	0.00172	CcSEcCtD
Tobramycin—Asthma—Epirubicin—bone cancer	0.00171	0.00171	CcSEcCtD
Tobramycin—Dehydration—Doxorubicin—bone cancer	0.00171	0.00171	CcSEcCtD
Tobramycin—Paraesthesia—Cisplatin—bone cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Methotrexate—bone cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Eosinophilia—Epirubicin—bone cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Dyspnoea—Cisplatin—bone cancer	0.00169	0.00169	CcSEcCtD
Tobramycin—Dry skin—Doxorubicin—bone cancer	0.00168	0.00168	CcSEcCtD
Tobramycin—Hypokalaemia—Doxorubicin—bone cancer	0.00167	0.00167	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Decreased appetite—Cisplatin—bone cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Bronchitis—Epirubicin—bone cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Cisplatin—bone cancer	0.00164	0.00164	CcSEcCtD
Tobramycin—Infestation NOS—Methotrexate—bone cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Infestation—Methotrexate—bone cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Pain—Cisplatin—bone cancer	0.00162	0.00162	CcSEcCtD
Tobramycin—Muscular weakness—Doxorubicin—bone cancer	0.00162	0.00162	CcSEcCtD
Tobramycin—Renal failure—Methotrexate—bone cancer	0.0016	0.0016	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Epirubicin—bone cancer	0.00159	0.00159	CcSEcCtD
Tobramycin—Stomatitis—Methotrexate—bone cancer	0.00159	0.00159	CcSEcCtD
Tobramycin—Asthma—Doxorubicin—bone cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Eosinophilia—Doxorubicin—bone cancer	0.00157	0.00157	CcSEcCtD
Tobramycin—Feeling abnormal—Cisplatin—bone cancer	0.00156	0.00156	CcSEcCtD
Tobramycin—Weight decreased—Epirubicin—bone cancer	0.00155	0.00155	CcSEcCtD
Tobramycin—Epistaxis—Methotrexate—bone cancer	0.00154	0.00154	CcSEcCtD
Tobramycin—Infestation NOS—Epirubicin—bone cancer	0.00153	0.00153	CcSEcCtD
Tobramycin—Infestation—Epirubicin—bone cancer	0.00153	0.00153	CcSEcCtD
Tobramycin—Bronchitis—Doxorubicin—bone cancer	0.00152	0.00152	CcSEcCtD
Tobramycin—Agranulocytosis—Methotrexate—bone cancer	0.00152	0.00152	CcSEcCtD
Tobramycin—Renal failure—Epirubicin—bone cancer	0.0015	0.0015	CcSEcCtD
Tobramycin—Body temperature increased—Cisplatin—bone cancer	0.0015	0.0015	CcSEcCtD
Tobramycin—Neuropathy peripheral—Epirubicin—bone cancer	0.0015	0.0015	CcSEcCtD
Tobramycin—Stomatitis—Epirubicin—bone cancer	0.00149	0.00149	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Pharyngitis—Methotrexate—bone cancer	0.00145	0.00145	CcSEcCtD
Tobramycin—Urinary tract disorder—Methotrexate—bone cancer	0.00145	0.00145	CcSEcCtD
Tobramycin—Epistaxis—Epirubicin—bone cancer	0.00144	0.00144	CcSEcCtD
Tobramycin—Urethral disorder—Methotrexate—bone cancer	0.00144	0.00144	CcSEcCtD
Tobramycin—Weight decreased—Doxorubicin—bone cancer	0.00143	0.00143	CcSEcCtD
Tobramycin—Sinusitis—Epirubicin—bone cancer	0.00143	0.00143	CcSEcCtD
Tobramycin—Agranulocytosis—Epirubicin—bone cancer	0.00143	0.00143	CcSEcCtD
Tobramycin—Infestation NOS—Doxorubicin—bone cancer	0.00141	0.00141	CcSEcCtD
Tobramycin—Infestation—Doxorubicin—bone cancer	0.00141	0.00141	CcSEcCtD
Tobramycin—Visual impairment—Methotrexate—bone cancer	0.00141	0.00141	CcSEcCtD
Tobramycin—Hypersensitivity—Cisplatin—bone cancer	0.0014	0.0014	CcSEcCtD
Tobramycin—Renal failure—Doxorubicin—bone cancer	0.00139	0.00139	CcSEcCtD
Tobramycin—Neuropathy peripheral—Doxorubicin—bone cancer	0.00139	0.00139	CcSEcCtD
Tobramycin—Stomatitis—Doxorubicin—bone cancer	0.00138	0.00138	CcSEcCtD
Tobramycin—Rhinitis—Epirubicin—bone cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Eye disorder—Methotrexate—bone cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Tinnitus—Methotrexate—bone cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Asthenia—Cisplatin—bone cancer	0.00136	0.00136	CcSEcCtD
Tobramycin—Pharyngitis—Epirubicin—bone cancer	0.00136	0.00136	CcSEcCtD
Tobramycin—Urinary tract disorder—Epirubicin—bone cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Connective tissue disorder—Epirubicin—bone cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Urethral disorder—Epirubicin—bone cancer	0.00134	0.00134	CcSEcCtD
Tobramycin—Epistaxis—Doxorubicin—bone cancer	0.00133	0.00133	CcSEcCtD
Tobramycin—Angiopathy—Methotrexate—bone cancer	0.00133	0.00133	CcSEcCtD
Tobramycin—Sinusitis—Doxorubicin—bone cancer	0.00133	0.00133	CcSEcCtD
Tobramycin—Immune system disorder—Methotrexate—bone cancer	0.00132	0.00132	CcSEcCtD
Tobramycin—Visual impairment—Epirubicin—bone cancer	0.00132	0.00132	CcSEcCtD
Tobramycin—Mediastinal disorder—Methotrexate—bone cancer	0.00132	0.00132	CcSEcCtD
Tobramycin—Agranulocytosis—Doxorubicin—bone cancer	0.00132	0.00132	CcSEcCtD
Tobramycin—Diarrhoea—Cisplatin—bone cancer	0.0013	0.0013	CcSEcCtD
Tobramycin—Eye disorder—Epirubicin—bone cancer	0.00128	0.00128	CcSEcCtD
Tobramycin—Tinnitus—Epirubicin—bone cancer	0.00128	0.00128	CcSEcCtD
Tobramycin—Erythema—Methotrexate—bone cancer	0.00128	0.00128	CcSEcCtD
Tobramycin—Rhinitis—Doxorubicin—bone cancer	0.00127	0.00127	CcSEcCtD
Tobramycin—Pharyngitis—Doxorubicin—bone cancer	0.00126	0.00126	CcSEcCtD
Tobramycin—Urinary tract disorder—Doxorubicin—bone cancer	0.00125	0.00125	CcSEcCtD
Tobramycin—Dysgeusia—Methotrexate—bone cancer	0.00125	0.00125	CcSEcCtD
Tobramycin—Connective tissue disorder—Doxorubicin—bone cancer	0.00125	0.00125	CcSEcCtD
Tobramycin—Angiopathy—Epirubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Tobramycin—Urethral disorder—Doxorubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Tobramycin—Immune system disorder—Epirubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Tobramycin—Mediastinal disorder—Epirubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Tobramycin—Back pain—Methotrexate—bone cancer	0.00123	0.00123	CcSEcCtD
Tobramycin—Visual impairment—Doxorubicin—bone cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Vomiting—Cisplatin—bone cancer	0.00121	0.00121	CcSEcCtD
Tobramycin—Vision blurred—Methotrexate—bone cancer	0.0012	0.0012	CcSEcCtD
Tobramycin—Rash—Cisplatin—bone cancer	0.0012	0.0012	CcSEcCtD
Tobramycin—Dermatitis—Cisplatin—bone cancer	0.00119	0.00119	CcSEcCtD
Tobramycin—Erythema—Epirubicin—bone cancer	0.00119	0.00119	CcSEcCtD
Tobramycin—Eye disorder—Doxorubicin—bone cancer	0.00119	0.00119	CcSEcCtD
Tobramycin—Ill-defined disorder—Methotrexate—bone cancer	0.00118	0.00118	CcSEcCtD
Tobramycin—Tinnitus—Doxorubicin—bone cancer	0.00118	0.00118	CcSEcCtD
Tobramycin—Anaemia—Methotrexate—bone cancer	0.00118	0.00118	CcSEcCtD
Tobramycin—Dysgeusia—Epirubicin—bone cancer	0.00117	0.00117	CcSEcCtD
Tobramycin—Back pain—Epirubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Tobramycin—Angiopathy—Doxorubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Tobramycin—Malaise—Methotrexate—bone cancer	0.00115	0.00115	CcSEcCtD
Tobramycin—Immune system disorder—Doxorubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Tobramycin—Vertigo—Methotrexate—bone cancer	0.00115	0.00115	CcSEcCtD
Tobramycin—Mediastinal disorder—Doxorubicin—bone cancer	0.00114	0.00114	CcSEcCtD
Tobramycin—Leukopenia—Methotrexate—bone cancer	0.00114	0.00114	CcSEcCtD
Tobramycin—Nausea—Cisplatin—bone cancer	0.00113	0.00113	CcSEcCtD
Tobramycin—Vision blurred—Epirubicin—bone cancer	0.00112	0.00112	CcSEcCtD
Tobramycin—Cough—Methotrexate—bone cancer	0.00111	0.00111	CcSEcCtD
Tobramycin—Ill-defined disorder—Epirubicin—bone cancer	0.00111	0.00111	CcSEcCtD
Tobramycin—Erythema—Doxorubicin—bone cancer	0.0011	0.0011	CcSEcCtD
Tobramycin—Anaemia—Epirubicin—bone cancer	0.0011	0.0011	CcSEcCtD
Tobramycin—Chest pain—Methotrexate—bone cancer	0.00109	0.00109	CcSEcCtD
Tobramycin—Myalgia—Methotrexate—bone cancer	0.00109	0.00109	CcSEcCtD
Tobramycin—Dysgeusia—Doxorubicin—bone cancer	0.00108	0.00108	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00108	0.00108	CcSEcCtD
Tobramycin—Malaise—Epirubicin—bone cancer	0.00108	0.00108	CcSEcCtD
Tobramycin—Discomfort—Methotrexate—bone cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Vertigo—Epirubicin—bone cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Leukopenia—Epirubicin—bone cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Back pain—Doxorubicin—bone cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Confusional state—Methotrexate—bone cancer	0.00105	0.00105	CcSEcCtD
Tobramycin—Cough—Epirubicin—bone cancer	0.00104	0.00104	CcSEcCtD
Tobramycin—Anaphylactic shock—Methotrexate—bone cancer	0.00104	0.00104	CcSEcCtD
Tobramycin—Vision blurred—Doxorubicin—bone cancer	0.00104	0.00104	CcSEcCtD
Tobramycin—Ill-defined disorder—Doxorubicin—bone cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Nervous system disorder—Methotrexate—bone cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Anaemia—Doxorubicin—bone cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Thrombocytopenia—Methotrexate—bone cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Chest pain—Epirubicin—bone cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Myalgia—Epirubicin—bone cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Skin disorder—Methotrexate—bone cancer	0.00101	0.00101	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00101	0.00101	CcSEcCtD
Tobramycin—Discomfort—Epirubicin—bone cancer	0.001	0.001	CcSEcCtD
Tobramycin—Malaise—Doxorubicin—bone cancer	0.000996	0.000996	CcSEcCtD
Tobramycin—Vertigo—Doxorubicin—bone cancer	0.000992	0.000992	CcSEcCtD
Tobramycin—Anorexia—Methotrexate—bone cancer	0.000992	0.000992	CcSEcCtD
Tobramycin—Leukopenia—Doxorubicin—bone cancer	0.000989	0.000989	CcSEcCtD
Tobramycin—Confusional state—Epirubicin—bone cancer	0.000982	0.000982	CcSEcCtD
Tobramycin—Anaphylactic shock—Epirubicin—bone cancer	0.000974	0.000974	CcSEcCtD
Tobramycin—Cough—Doxorubicin—bone cancer	0.000964	0.000964	CcSEcCtD
Tobramycin—Nervous system disorder—Epirubicin—bone cancer	0.000955	0.000955	CcSEcCtD
Tobramycin—Thrombocytopenia—Epirubicin—bone cancer	0.000954	0.000954	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000948	0.000948	CcSEcCtD
Tobramycin—Skin disorder—Epirubicin—bone cancer	0.000946	0.000946	CcSEcCtD
Tobramycin—Chest pain—Doxorubicin—bone cancer	0.00094	0.00094	CcSEcCtD
Tobramycin—Myalgia—Doxorubicin—bone cancer	0.00094	0.00094	CcSEcCtD
Tobramycin—Paraesthesia—Methotrexate—bone cancer	0.000935	0.000935	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000934	0.000934	CcSEcCtD
Tobramycin—Discomfort—Doxorubicin—bone cancer	0.000929	0.000929	CcSEcCtD
Tobramycin—Anorexia—Epirubicin—bone cancer	0.000929	0.000929	CcSEcCtD
Tobramycin—Dyspnoea—Methotrexate—bone cancer	0.000928	0.000928	CcSEcCtD
Tobramycin—Confusional state—Doxorubicin—bone cancer	0.000909	0.000909	CcSEcCtD
Tobramycin—Decreased appetite—Methotrexate—bone cancer	0.000905	0.000905	CcSEcCtD
Tobramycin—Anaphylactic shock—Doxorubicin—bone cancer	0.000901	0.000901	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Methotrexate—bone cancer	0.000899	0.000899	CcSEcCtD
Tobramycin—Pain—Methotrexate—bone cancer	0.00089	0.00089	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000887	0.000887	CcSEcCtD
Tobramycin—Nervous system disorder—Doxorubicin—bone cancer	0.000884	0.000884	CcSEcCtD
Tobramycin—Thrombocytopenia—Doxorubicin—bone cancer	0.000882	0.000882	CcSEcCtD
Tobramycin—Skin disorder—Doxorubicin—bone cancer	0.000875	0.000875	CcSEcCtD
Tobramycin—Paraesthesia—Epirubicin—bone cancer	0.000875	0.000875	CcSEcCtD
Tobramycin—Dyspnoea—Epirubicin—bone cancer	0.000868	0.000868	CcSEcCtD
Tobramycin—Anorexia—Doxorubicin—bone cancer	0.000859	0.000859	CcSEcCtD
Tobramycin—Feeling abnormal—Methotrexate—bone cancer	0.000858	0.000858	CcSEcCtD
Tobramycin—Gastrointestinal pain—Methotrexate—bone cancer	0.000851	0.000851	CcSEcCtD
Tobramycin—Decreased appetite—Epirubicin—bone cancer	0.000847	0.000847	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Epirubicin—bone cancer	0.000841	0.000841	CcSEcCtD
Tobramycin—Pain—Epirubicin—bone cancer	0.000833	0.000833	CcSEcCtD
Tobramycin—Urticaria—Methotrexate—bone cancer	0.000827	0.000827	CcSEcCtD
Tobramycin—Abdominal pain—Methotrexate—bone cancer	0.000823	0.000823	CcSEcCtD
Tobramycin—Body temperature increased—Methotrexate—bone cancer	0.000823	0.000823	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000821	0.000821	CcSEcCtD
Tobramycin—Paraesthesia—Doxorubicin—bone cancer	0.000809	0.000809	CcSEcCtD
Tobramycin—Dyspnoea—Doxorubicin—bone cancer	0.000804	0.000804	CcSEcCtD
Tobramycin—Feeling abnormal—Epirubicin—bone cancer	0.000803	0.000803	CcSEcCtD
Tobramycin—Gastrointestinal pain—Epirubicin—bone cancer	0.000797	0.000797	CcSEcCtD
Tobramycin—Decreased appetite—Doxorubicin—bone cancer	0.000784	0.000784	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000778	0.000778	CcSEcCtD
Tobramycin—Urticaria—Epirubicin—bone cancer	0.000774	0.000774	CcSEcCtD
Tobramycin—Pain—Doxorubicin—bone cancer	0.000771	0.000771	CcSEcCtD
Tobramycin—Abdominal pain—Epirubicin—bone cancer	0.00077	0.00077	CcSEcCtD
Tobramycin—Body temperature increased—Epirubicin—bone cancer	0.00077	0.00077	CcSEcCtD
Tobramycin—Hypersensitivity—Methotrexate—bone cancer	0.000767	0.000767	CcSEcCtD
Tobramycin—Asthenia—Methotrexate—bone cancer	0.000747	0.000747	CcSEcCtD
Tobramycin—Feeling abnormal—Doxorubicin—bone cancer	0.000743	0.000743	CcSEcCtD
Tobramycin—Gastrointestinal pain—Doxorubicin—bone cancer	0.000737	0.000737	CcSEcCtD
Tobramycin—Pruritus—Methotrexate—bone cancer	0.000736	0.000736	CcSEcCtD
Tobramycin—Hypersensitivity—Epirubicin—bone cancer	0.000718	0.000718	CcSEcCtD
Tobramycin—Urticaria—Doxorubicin—bone cancer	0.000716	0.000716	CcSEcCtD
Tobramycin—Body temperature increased—Doxorubicin—bone cancer	0.000713	0.000713	CcSEcCtD
Tobramycin—Abdominal pain—Doxorubicin—bone cancer	0.000713	0.000713	CcSEcCtD
Tobramycin—Diarrhoea—Methotrexate—bone cancer	0.000712	0.000712	CcSEcCtD
Tobramycin—Asthenia—Epirubicin—bone cancer	0.000699	0.000699	CcSEcCtD
Tobramycin—Pruritus—Epirubicin—bone cancer	0.000689	0.000689	CcSEcCtD
Tobramycin—Dizziness—Methotrexate—bone cancer	0.000688	0.000688	CcSEcCtD
Tobramycin—Diarrhoea—Epirubicin—bone cancer	0.000666	0.000666	CcSEcCtD
Tobramycin—Hypersensitivity—Doxorubicin—bone cancer	0.000664	0.000664	CcSEcCtD
Tobramycin—Vomiting—Methotrexate—bone cancer	0.000662	0.000662	CcSEcCtD
Tobramycin—Rash—Methotrexate—bone cancer	0.000656	0.000656	CcSEcCtD
Tobramycin—Dermatitis—Methotrexate—bone cancer	0.000656	0.000656	CcSEcCtD
Tobramycin—Headache—Methotrexate—bone cancer	0.000652	0.000652	CcSEcCtD
Tobramycin—Asthenia—Doxorubicin—bone cancer	0.000647	0.000647	CcSEcCtD
Tobramycin—Dizziness—Epirubicin—bone cancer	0.000644	0.000644	CcSEcCtD
Tobramycin—Pruritus—Doxorubicin—bone cancer	0.000638	0.000638	CcSEcCtD
Tobramycin—Vomiting—Epirubicin—bone cancer	0.000619	0.000619	CcSEcCtD
Tobramycin—Nausea—Methotrexate—bone cancer	0.000618	0.000618	CcSEcCtD
Tobramycin—Diarrhoea—Doxorubicin—bone cancer	0.000617	0.000617	CcSEcCtD
Tobramycin—Rash—Epirubicin—bone cancer	0.000614	0.000614	CcSEcCtD
Tobramycin—Dermatitis—Epirubicin—bone cancer	0.000614	0.000614	CcSEcCtD
Tobramycin—Headache—Epirubicin—bone cancer	0.00061	0.00061	CcSEcCtD
Tobramycin—Dizziness—Doxorubicin—bone cancer	0.000596	0.000596	CcSEcCtD
Tobramycin—Nausea—Epirubicin—bone cancer	0.000579	0.000579	CcSEcCtD
Tobramycin—Vomiting—Doxorubicin—bone cancer	0.000573	0.000573	CcSEcCtD
Tobramycin—Rash—Doxorubicin—bone cancer	0.000568	0.000568	CcSEcCtD
Tobramycin—Dermatitis—Doxorubicin—bone cancer	0.000568	0.000568	CcSEcCtD
Tobramycin—Headache—Doxorubicin—bone cancer	0.000565	0.000565	CcSEcCtD
Tobramycin—Nausea—Doxorubicin—bone cancer	0.000535	0.000535	CcSEcCtD
